Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q3 2021 Earnings Presentation
7 slides from Sanara Medtech's earnings presentation, Nov 15, 2021
Slide 1: Q3 2021 Earnings and Business Update Call
Q3 2021 Earnings and Business Update Call
Slide 2: Disclaimers
*. Sanara MedTech Disclaimers ‘This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, of state other information relating to Sanara MedTech inc. (the "Company," *Sanara,” “we,” “our” of ‘us").
Slide 3: Overview: Commentary on Q3 2021
Overview «3. Sanara MedTech Commentary on Q3 2021 Financial Update + Second highest sales quarter in Company's history with $5.8 million in revenue + Net loss of $2.0 million largely due to increased SG&A ($1.8 million higher than previous year) + ~70% of higher SG&A was due to increased direct sale
Slide 4: Surgical Products
Surgical Products Surgical Overview + 29 Regional Sales Managers (“RSMs”) and Territory Sales Managers (“TSMs”) at September 30, 2021 CellerateRX Surgical sold in over 395 hospitals/ASCs for the nine months ended September 30, 2021 CellerateRX Surgical sold in hospitals/ASCs across 21 states) as of
Slide 5: Cook - Sanara Partnership Product Launch
Sanara MedTech Cook - Sanara Partnership Product Launch + In November 2021 Sanara announced the commercial launch of two new innovative products from Cook Biotech Inc.: — FORTIFY TRG™ Tissue Repair Graft — FORTIFY FLOWABLE™ Extracellular Matrix FORTIFY TRG™ Tissue Repair Graft FORTIFY FLOWABLE™ Extr
Slide 6: Q3 2021 Financial Highlights
Sanara MedTech Q3 2021 Financial Highlights Overview + Revenue + Q3 2021 revenue was $5,823,942 compared to revenues of $4,306,324 for Q3 2020, representing a 35% increase from the prior year period. + For the nine months ended September 30, 2021, revenues totaled $17,110,511 compared to revenues of
Slide 7: Questions
Questions . Sanara MedTech Evidence Based Healing